Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach
European Cardiology Review · 19.06.2024 · 19
DOI: 10.15420/ecr.2023.34 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 19.06.2024. Verfasst von Carmen Lara-Romero und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department, Virgen del Rocío University Hospital Seville, Spain. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The terms non-alcoholic fatty liver disease and non-alcoholic steatohepatitis have some limitations as they use exclusionary confounder terms and the use of potentially stigmatising language. Recently, a study with content experts and patients has been set to change this nomenclature. The term chosen to replace non-alcoholic fatty liver disease was metabolic dysfunction-associated steatotic liver disease (MASLD), which avoids stigmatising and helps improve awareness and patient identification. MASLD is the most common cause of chronic liver disease with an increasing prevalence, accounting for 25% of the global population. It is considered the hepatic manifestation of the metabolic syndrome with lifestyle playing a fundamental role in its physiopathology. Diet change and physical activity are the cornerstones of treatment, encompassing weight loss and healthier behaviours and a holistic approach. In Europe, there is no approved drug for MASLD to date and there is a substantial unmet medical need for effective treatments for patients with MASLD. This review not only provides an update on advances in evidence for nutrition and physical activity interventions but also explores the different therapeutic options that are being investigated and whose development focuses on the restitution of metabolic derangements and halting inflammatory and fibrogenic pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Department, Virgen del Rocío University Hospital Seville, Spain.
- Clinical and Translational Research in Digestive Diseases, Institute of Biomedicine of Seville, University of Seville Seville, Spain.
Zitieren
APA
Lara-Romero, C., & Romero-Gómez, M. (2024). Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach. European Cardiology Review, 19. https://doi.org/10.15420/ecr.2023.34
Vancouver
Lara-Romero C, Romero-Gómez M. Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach. European Cardiology Review. 2024;19. doi:10.15420/ecr.2023.34
BibTeX
@article{LaraRomero2024,
author = {Lara-Romero, Carmen and Romero-Gómez, Manuel},
title = {Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach},
journal = {European Cardiology Review},
year = {2024},
volume = {19},
doi = {10.15420/ecr.2023.34}
}
EUVIMED